Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359953 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD17B10EPHX1PDK1PDK2 | |
| SCHEMBL16544829 | 0.94 | ADH1B (0.31) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL12359975 | 0.88 | — | — | |
| SCHEMBL12359986 | 0.77 | MAPK1 (0.33) | — | |
| SCHEMBL12543667 | 0.77 | EPHX2 (0.39) | — | |
| SCHEMBL236481 | 0.77 | ALDH1A1 (0.32) | ALDH1A1HSD17B10EPHX1 | |
| SCHEMBL7778181 | 0.77 | ALDH1A1 (0.40) | ALDH1A1HSD17B10EPHX1PDK1PDK2 | |
| SCHEMBL236416 | 0.75 | ALDH1A1 (0.36) | ALDH1A1HSD17B10EPHX1PDK1PDK2 | |
| SCHEMBL17822022 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HSD17B10EPHX1PDK1PDK2 | |
| SCHEMBL50080 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10EPHX1PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2716635-B1 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-8735430-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735430-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20130030022-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-8299103-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030022-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885HSD17B10 2080/4885EPHX1 873/4885 |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885HSD17B10 2080/4885EPHX1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.